Inside My Portfolio: 16 Positions I'm Holding as 2025 Comes to an End
Here's an update on a bunch of names I currently hold from biotech to batteries to tech and turnaround stories.
You're reading 0 of 1 free page.
Register to read more or Unlock Pro — 50% Off Ends Soon
Investors are digesting some interesting economic news Tuesday morning. GDP was much hotter than expected, but inflationary pressures also increased. The odds of a Fed interest rate cut in January are slightly reduced, and indexes are flat to down.
As we approach the end of the year, I wanted to provide an update on stocks I have mentioned and still hold. It is important to note that I am not a buy-and-hold investor. I manage risk by actively trading in various time frames, and my position sizes are constantly changing. Just because I’m holding a stock doesn’t mean that I’m short-term bullish. I’m always looking and waiting for setups and trading opportunities. If you are a passive investor, most of the stocks I hold are very high risk.
Here are 16 positions I am currently holding. I’ll have more on Friday.
Abivax (ABVX) is hitting new highs on takeover speculation. The stock traded with a slight uptrend after big news back in July and is now accelerating on rumors that Lilly (LLY) is negotiating a deal. I slightly reduced my position on the strength and will look to add back if an opportunity arises.
ADMA Biologics (ADMA) struggled all year but finally came back to life after third-quarter earnings. It is now consolidating a sizable move. The company is forecast to grow EPS by 50% in 2026 and appears to be a value. I’ll be ramping up my position again as the chart develops.
Alto Neuroscience (ANRO) is one of my top picks for 2026. It was recently up about 40% and I reduced my position. I’ll be adding back as new entry points develop. The company will have several data events to serve as catalysts in the year ahead.
BridgeBio Pharma (BBIO) has been a steady performer and is at an all-time high in anticipation of huge revenue and EPS growth. I’ve reduced my position slightly and would like to see some consolidation before fourth-quarter earnings.
Dutch Bros (BROS) is a newer position that I bottom-fished in October. Part of the issue was coffee prices, but it had some management struggles as well. It appears they are turning things around and should show steady revenue growth of at least 25%. I’ll be watching for chart development.
CorMedix (CRMD) had huge numbers and has a P/E of just nine and an EPS estimate of $2.54 for 2026. However, there is uncertainty about insurance reimbursements, and it is unclear if it can maintain its profit margins. I think the market is overly pessimistic and that the company will surprise the skeptics
Delcath Systems (DCTH) is another top pick for 2026. It trades very thin but is off recent lows and over the 50-day moving average. I’ll be watching for chart development and expect to see positive news when it announces earnings.
Duos Technologies (DUOT) is an edge computing play that is very under the radar. It is just turning profitable and is seeing a large ramp in revenues. I’m looking for opportunities to buy on weakness.
Emergent BioSolutions (EBS) is a turnaround play that has done a great job of reinventing itself. The stock is at the highs, and I have reduced it as I await an opportunity to add back shares.
Electrovaya (ELVA) is a little battery play that has finally gotten some recognition as it opens a new manufacturing facility in New York. It moves strongly on earnings, and I’m watching for it to consolidate near the highs.
EOS Energy (EOSE) is also a battery play and is struggling to hold support. The company is now recognizing revenue, and I expect traders to come back to the name when there is some news flow.
Flotek Industries (FTK) provides chemicals to increase oil and gas production, but its growth engine is AI-related data analytics. It is often lumped in with oil service even though its growth is unrelated to oil prices. It is looking solid, and I intend to increase my position.
Harrow (HROW) was a top pick for me in the third quarter, but it suffered a sharp pullback as expectations were too high. It has now recovered and is forming a nice-looking cup-with-handle pattern. I’ll be adding to this aggressively depending on market conditions.
Alphabet (GOOGL) , Nvidia (NVDA) , Amazon (AMZN) . I own these three Magnificent Seven names to varying degrees primarily as a way to increase exposure quickly when I believe market conditions are good. They are an easy place to park cash while waiting for other setups to develop. I believe that Amazon will be the standout performer in the Mag 7 Group in 2026.
I’ll have updates on more of my holdings on Friday.
At the time of publication, Rev Shark was long GOOGL, NVDA, AMZN, ABVX, ADMA, ANRO, BBIO, BROS, CRMD, DCTH, DUOT, EBS, ELVA, EOSE, FTK, HROW.
Please note that due to factors including low market capitalization and/or insufficient public float, we consider many of these names to be small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.
